Disrupting the PNPLA3-ABHD5 Interaction Stimulates Lipolysis and Improves PNPLA3-I148M-Associated Hepatic Steatosis.

Authors

Simon Steinbring Hoffman, Emily Tso Newman, Daniel Lin, Michelle Chen, Song Yang, Alan Cheng, Thomas W Rosahl, Heather H Zhou, Saswata Talukdar, Yingjiang Zhou

Published in

Diabetes. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

We evaluate the importance of the protein-protein interaction (PPI) between PNPLA3-I148M and its cofactor α/β-hydrolase domain-containing protein 5 (ABHD5) in PNPLA3-I148M-mediated hepatic steatosis. We demonstrate that disrupting the PNPLA3-ABHD5 PPI improves I148M-associated steatosis and markers of liver injury. This work supports the development of therapies targeting the PNPLA3-ABHD5 PPI for the treatment of PNPLA3-I148M-associated metabolic dysfunction-associated steatotic liver disease.

PMID:
42900750
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.